Author(s):
Payal N. Vaja, Vivek P. Solanki, Dilip R. Ghusar, Siddhi K. Upadhyay, Harsh H madiya
Email(s):
payalvaja55@gmail.com
DOI:
10.52711/2231-5659.2025.00056 
Address:
Payal N. Vaja1*, Vivek P. Solanki2, Dilip R. Ghusar2, Siddhi K. Upadhyay2, Harsh H madiya2
1Assistant Professor, School of Phamacy, Dr. Subhash University, Junagadh- 362001, Gujarat, India.
2Research Scholar, School of Pharmacy, Dr. Subhash University, Junagadh- 362001, Gujarat, India.
*Corresponding Author
Published In:
Volume - 15,
Issue - 4,
Year - 2025
ABSTRACT:
Inflammatory Bowel Disease (IBD), encompassing Crohn’s Disease (CD) and Ulcerative Colitis (UC), is a persistent and relapsing inflammatory disorder of the gastrointestinal (GI) tract. Though the exact cause remains unidentified, various factors such as genetic predisposition, environmental influences, immune dysfunction, and alterations in gut microbiota are believed to play key roles in disease onset. CD may affect any portion of the GI tract, especially the ileum and colon, with patchy and deep tissue inflammation. In contrast, UC is limited to the colon and involves continuous inflammation of the mucosal lining. Both conditions are characterized by symptoms like abdominal pain, diarrhoea, fatigue, and weight loss, and may lead to serious complications including strictures, fistulas, and an elevated risk of colorectal cancer. Conventional treatments include anti-inflammatory drugs, immunosuppressants, lifestyle modifications, and surgery. However, limitations such as side effects and inconsistent therapeutic outcomes have prompted interest in alternative strategies. Indian medicinal plants have emerged as promising options due to their anti-inflammatory, antioxidant, immunomodulatory, and gut-healing properties. This review explores the therapeutic potential of ten key plants, including Withaniasomnifera, Curcuma longa, Nigella sativa, and Boswellia serrata. Their bioactive compounds target inflammatory pathways and support mucosal protection, offering a natural and complementary approach to IBD management. Integrating traditional herbal remedies with modern treatment could enhance patient outcomes and promote holistic care.
Cite this article:
Payal N. Vaja, Vivek P. Solanki, Dilip R. Ghusar, Siddhi K. Upadhyay, Harsh H madiya. Healing Herbs: A Review of Herbal Treatments for Inflammatory Bowel Disease. Asian Journal of Research in Pharmaceutical Sciences. 2025; 15(4):381-7. doi: 10.52711/2231-5659.2025.00056
Cite(Electronic):
Payal N. Vaja, Vivek P. Solanki, Dilip R. Ghusar, Siddhi K. Upadhyay, Harsh H madiya. Healing Herbs: A Review of Herbal Treatments for Inflammatory Bowel Disease. Asian Journal of Research in Pharmaceutical Sciences. 2025; 15(4):381-7. doi: 10.52711/2231-5659.2025.00056 Available on: https://ajpsonline.com/AbstractView.aspx?PID=2025-15-4-6
REFERENCES:
1. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012; Jan 1; 142(1): 46–54.e42. doi: 10.1053/j.gastro.2011.10.010.
2. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population based studies. Lancet. 2017; Oct 1; 390(10114): 2769–2778. doi: 10.1016/S0140-6736(17)32448-0.
3. Ng SC, Kaplan GG, Tang W, Banerjee R, Adigopula B, Underwood FE, et al. Population density and risk of inflammatory bowel disease: a prospective populationbased study in 13 countries or regions in AsiaPacific. Am J Gastroenterol. 2019 Jan 1; 114(1): 107–115. doi: 10.14309/ajg.0000000000000120.
4. Wilks S, Moxon W. Lectures on pathological anatomy. Longmans, Green; 1889.
5. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis; a pathologic and clinical entity. Am J Med. 1952 May 1;13(5):583–590.
6. Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015 Apr 1;12(4):205–217. doi: 10.1038/nrgastro.2015.24.
7. Deshmukh R, Kumari S, Harwansh RK. Inflammatory Bowel Disease: A Snapshot of Current Knowledge. Res J Pharm Technol. 2020;13(4):1808. doi:10.5958/0974-360X.2020.00180.8
8. Singh NK. Ulcerative Colitis: A Comprehensive Review. Res J Pharm Technol. 2021;14(3):212. doi:10.5958/0974-360X.2021.00212.2
9. Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, et al. Third European evidence based consensus on diagnosis and management of ulcerative colitis Part 2: current management. J Crohn’s Colitis. 2017 Jul 1;11(7):769–784. doi: 10.1093/ecco-jcc/jjx108.
10. Sauk J. Diet and microbiome in inflammatory bowel diseases. In: Nutritional management of inflammatory bowel diseases. Springer; 2016. p. 3–16.
11. Danese S, Banerjee R, Cummings JF, Dotan I, Kotze PG, Leong RWL, et al. Consensus recommendations for patient centered therapy in mild to moderate ulcerative colitis: the i Support Therapy Access to Rapid Treatment (iSTART) approach. Intest Res. 2018 Oct 1;16(4):522.
12. Flamant M, Roblin X. Laboratory evaluation, including novel diagnostic markers. In: Crohn’s disease and ulcerative colitis. Springer; 2017. p. 233–242.
13. Cushing K, Higgins PD. Management of Crohn disease: a review. JAMA. 2021 Jan 1;325(1):69–80.
14. Di Paolo A, Luci G. Personalized medicine of monoclonal antibodies in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring, and beyond. Front Pharmacol. 2020 Dec 10;11:610806.
15. Jain P, Parkhe G. Alternative Colon Targeted Drug Delivery Approaches for the Treatment of Inflammatory Bowel Disease. Res J Pharm Technol. 2020;13(9):971. doi:10.5958/0974-360X.2020.00971.3
16. Zanke NA, Dhekane T, Ghonge AB, Zanke AA, Akotakar A. A Review of Ulcerative Colitis. Int J Technol. 2022;7(1):8. doi:10.52711/2231-3915.2022.00008
17. Pande S, Vashi J, Solanki A. Formulation and Characterization of Ileo-colonic Targeted Mucoadhesive Microspheres Containing Flurbiprofen for Treatment of Ulcerative Colitis. Res J Pharm Technol. 2020;13(6):600. doi:10.5958/0974-360X.2020.00600.9
18. Mahore JG, Deshpande NV, Trivedi RV, Shelar AS. Ulcerative Colitis: Treatment Updates. Res J Pharm Technol. 2020;13(6):615. doi:10.5958/0974-360X.2020.00615.0
19. Deshmukh R. Development and In‑Vitro Evaluation of Colon Specific Indomethacin Matrix Tablet for the Treatment of Inflammatory Bowel Disease. Res J Pharm Technol. 2021;14(4):422. doi:10.52711/0974-360X.2021.00422
20. Govind Hublikar R, Holla SN, Minnamreddigari C. Ameliorative Effect of Aqueous Extract of Carica papaya Linn. Leaves on Acetic Acid Induced Ulcerative Colitis in Male Albino Wistar Rats. Res J Pharm Technol. 2023;16(3):353. doi:10.52711/0974-360X.2023.00353
21. Ariharasivakumar G, Karthikaa T, Nongkhlaw R, Packialakshmi P. Evaluation of Leaf Extracts of Simarouba glauca on Experimentally Induced Inflammatory Bowel Diseases in Wistar Rats. Res J Pharm Technol. 2020;13(3):340. doi:10.5958/0974-360X.2020.00340.6
22. Chandra S, Das A, Roy T, Bose P, Paul S, Mukherjee L, et al. Emergent Strategy in Management of Inflammatory Bowel Disease: A Narrowed in on Novel Drugs. Res J Pharm Technol. 2021;14(3):321. doi:10.5958/0974-360X.2021.00321.8
23. Chandra S, Roy T, Bose P, Ghosh S, Paul S, Roychowdhury V, et al. Protective Effect of Colocasia esculenta on TNBS Induced Ulcerative Colitis in Mice. Res J Pharm Technol. 2022;15(1):63. doi:10.52711/0974-360X.2022.00063
24. Nugraha D, Putri NAS, Visuddho, Wungu CDK. Comparison of Bacterial Composition, Concentration, and Metabolism of Short Chain Fatty Acid in Inflammatory Bowel Disease: A Systematic Review. Res J Pharm Technol. 2021;14(10):1038. doi:10.52711/0974-360X.2021.01038
25. Popaniya HS, Vaja PN. A concise review on herbal immunity booster. Asian J Pharm Res. 2024 Mar 1;14(3):2024.
26. Chandran S, Patwardhan B. Withania somnifera (Ashwagandha): A promising remedy for IBD. J Ethnopharmacol. 2021 Oct 1;274:113734.
27. Singh N, et al. Ashwagandha (Withania somnifera): A systematic review of its therapeutic potential and mechanisms of action. Phytother Res. 2020 Apr 1;34(4):811–823.
28. Vaja PN, Popaniya HS. A Systematic Review on Medicinal Plant Species to treat Pharyngitis. Asian J Pharm Technol. 2024 Jul–Sep;14(3).
29. Bhatia S, et al. Zingiber officinale (Ginger): A promising anti-inflammatory agent for IBD. Phytother Res. 2020 Mar 1;34(3):456–465.
30. Salem ML. Immunomodulatory and therapeutic properties of the Nigella sativa L. seed. Int Immunopharmacol. 2005 Jan 1;5(13):1735–1740.
31. Gholamnezhad Z, et al. A review of the pharmacological effects of Nigella sativa and its active constituents. Phytother Res. 2016 Aug 1;30(8):1259–1269.
32. Popaniya HS, Vaja PN. A basic Review on herbal plants for Sunscreen preparation. Res J Topical Cosmet Sci. 2024 Dec 1;15(2):2024.
33. Liu J, et al. Glycyrrhizin: A potential drug against inflammatory bowel disease. Food Chem Toxicol. 2019 Feb 1;125:333–341.
34. Isbrucker RA, Burdock GA. Risk and safety assessment on the consumption of licorice root (Glycyrrhiza sp.), its extract, and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin. Regul Toxicol Pharmacol. 2006 Jun 1;44(3):163–192.
35. Anwar F, et al. Moringa oleifera: A food plant with multiple medicinal uses. Phytother Res. 2007 Feb 1;21(2):104–107.
36. Vergara-Jimenez M, et al. Nutritional and therapeutic potential of Moringa oleifera leaves in improving the health and wellbeing of humans. Int J Mol Sci. 2017 Dec 1;18(12):2766.
37. Popaniya HS, Vaja PN. A Review on Herbal Components used for Polyherbal Facewash. Asian J Pharm Res. 2024 Mar 1;14(3):2024.
38. Holt PR, et al. Curcumin therapy in inflammatory bowel disease: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2020 Mar 1;18(3):528–537.
39. Hanai H, et al. Curcumin maintenance therapy for ulcerative colitis: Randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006 Jul 1;4(5):657–663.
40. Lynch WD, Hsu R. Ulcerative colitis. StatPearls. Treasure Island: StatPearls Publishing; 2022.
41. Conrad K, Roggenbuck D, Laass MW. Diagnosis and classification of ulcerative colitis. Autoimmun Rev. 2014 Apr 1;13(4–5):463–466.
42. Feuerstein JD, Cheifetz AS, editors. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clinic Proceedings. Elsevier; 2014.
43. Myrelid P, Landerholm K, Nordenvall C, Pinkney TD, Andersson RE. Appendectomy and the risk of colectomy in ulcerative colitis: a national cohort study. Am J Gastroenterol. 2017 Aug 1;112(8):1311–1319.
44. Parian A, Limketkai B, Koh J, Brant SR, Bitton A, Cho JH, et al. Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta analysis. Gut. 2017 Aug 1;66(8):1390–1397.
45. Vaja PN, Popaniya HS. The botanical breakthrough: herbal approaches to reversing alopecia. Asian J Pharm Res. 2024 Oct–Dec;14(4).
46. Vaja PN, Popaniya HS. Exploring the efficacy of herbal plants in nephrolithiasis: an in-depth review. Asian J Pharm Res. 2024 Jul–Sep;14(3).
47. Vaja PN, Borkhataria CH, Popaniya HS. A systematic review on medicinal plant species to treat pharyngitis. Asian J Pharm Technol. 2024 Jul–Sep;14(3).
48. Popaniya HS, Vaja PN. A concise review on herbal immunity booster. Asian J Pharm Res. 2024 Mar 1;14(3).
49. Bernstein CN, Eliakim A, Fedail S, Fried M, Gearry R, Goh K L, et al. World gastroenterology organization global guidelines inflammatory bowel disease: update August 2015. J Clin Gastroenterol. 2016 Oct 1;50(10):803–818.
50. Pandey VN, et al. Phytochemistry and pharmacology of Aegle marmelos. J Med Plants.
51. Singh B, Sahu P. Role of Aegle marmelos in IBD: A review. Pharmacogn Rev. 2023.